Research programme: Gram-negative antimicrobial peptide therapeutics - Aurobac Therapeutics
Alternative Names: ATX-2Latest Information Update: 22 Sep 2024
At a glance
- Originator Aurobac Therapeutics
- Class Antibacterials; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Gram-negative infections
Most Recent Events
- 02 Aug 2024 Early research in Gram-negative infections in France (Parenteral) (Aurobac Therapeutics pipeline;July 2024)